News Releases

Date Title and Summary Additional Formats
Toggle Summary HTG Molecular Diagnostics and OvaGene Oncology Partner on Gynecologic Cancer Tests
HTG Molecular Diagnostics and OvaGene Oncology Partner on Gynecologic Cancer Tests TUCSON, Ariz. (April 7, 2014)  HTG Molecular Diagnostics, Inc., (HTG) and OvaGene Oncology have entered a manufacturing supply agreement where OvaGene will design and develop their proprietary gene
View HTML
Toggle Summary Lewis Shuster Joins HTG Molecular Diagnostics Board of Directors
Lewis Shuster Joins HTG Molecular Diagnostics Board of Directors TUCSON, Ariz. (March 21, 2014) HTG Molecular Diagnostics, Inc., (HTG) today announced that Lewis (Lew) Shuster has joined its board of directors. Mr. Shuster is CEO of Shuster Capital, a strategic and operating advisory firm to life
View HTML
Toggle Summary HTG Molecular Diagnostics Completes Initial Series E Preferred Stock Offering
TUCSON, Ariz. (February 11, 2014) HTG Molecular Diagnostics (“HTG”) today announced the initial closing of its Series E offering with existing investors Novo Ventures, SROne, Merck Capital Ventures, and Fletcher Spaght. Proceeds will support commercial and product development initiatives.
View HTML
Toggle Summary The PROOF Centre of Excellence Partners with HTG Molecular Diagnostics to Begin Clinical Validation of Heart Transplant Rejection Blood Test
Tucson, Ariz. (September 25, 2013) - The Centre of Excellence for the Prevention of Organ Failure (PROOF Centre) and HTG Molecular Diagnostics are collaborating to begin clinical validation of a biomarker blood test that will provide early indication of organ rejection in heart transplant patients.
View HTML
Toggle Summary NIH Awards HTG Molecular Additional $1.01M to Continue Development of Targeted Sequencing Product Concept
TUCSON, Ariz. (September 4, 2013) – The National Human Genome Research Institute of the National Institutes of Health issued a Notice of Award granting a Phase II SBIR award of $1.01 million for HTG Molecular Diagnostics to continue the Nuclease Probe Mediated Sequencing Project (HTG EdgeSeq).
View HTML
Toggle Summary HTG Launches Two Multiplexed Gene Expression Assays For Use on Award-Winning HTG Edge System
TUCSON, Ariz. (July, 2013) – HTG Molecular Diagnostics , today announced the availability of two new multiplexed assays for drug and oncology research, coinciding with the successful completion of the first wave of installations of its MDEA award-winning HTG Edge System.
View HTML
Toggle Summary HTG Edge System Wins 2013 Silver Medical Design Excellence Award
TUCSON, Ariz. (June, 2013) – The Edge System, developed and commercialized by HTG Molecular Diagnostics, is the 2013 Silver Award recipient for in-Vitro Diagnostics in the 15th Annual Medical Design Excellence Awards competition. The HTG Edge System is the only automated RNA analysis platform that
View HTML
Toggle Summary HTG Molecular Diagnostics Edge System a Finalist for Medical Design Excellence Award
TUCSON, Ariz. (April, 2013) –The Edge System, developed by HTG Molecular Diagnostics, is a finalist in the 15th Annual Medical Design Excellence Awards competition. HTG Molecular Diagnostics is a privately held company specializing in RNA based diagnostics and solutions for translational research.
View HTML
Toggle Summary HTG Molecular Diagnostics and PROOF Centre Partner to Commercialize COPD Prognostic Test
TUCSON, Ariz. (November 27, 2012) – The Centre of Excellence for the Prevention of Organ Failure (PROOF Centre) and HTG Molecular Diagnostics have finalized a license agreement that provides HTG Molecular Diagnostics exclusive rights to commercialize PROOF Centre-developed gene expression blood
View HTML
Toggle Summary HTG Molecular Diagnostics Introduces the EDGE System at AMP Conference
TUCSON, Ariz. (October 18, 2012) – HTG Molecular Diagnostics will unveil the EDGE system at the AMP conference in Long Beach, October 25 – 27, 2012. The EDGE system is the first fully-automated instrumentation designed for clinical and research laboratories that offers nucleic acid extraction-free
View HTML